+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

DNA Vaccine Market by Product Type, Type and End User: Global Opportunity Analysis and Industry Forecast, 2021-2030

  • PDF Icon

    Report

  • 123 Pages
  • December 2021
  • Region: Global
  • Allied Market Research
  • ID: 5548379
The global DNA vaccine market was valued at $422.77 million in 2020 and is projected to reach $774.43 million by 2030 registering a CAGR of 6.3% from 2021 to 2030.



DNA vaccines is a small, circular DNA plasmid that encodes one or more protein antigens under the control of a promoter to produce a specific immune response against disease. DNA vaccines are the third-generation vaccines specifically designed to overcome the unsought properties of conventional vaccines. Increase in vulnerability of the population to infectious diseases and rise in number of antibiotics-resistant pathogens have created the need for effective and low-cost vaccination, which would provide long-lasting immunity.

The main driving factors of the DNA vaccines market include, rise in prevalence of cancer and infectious diseases in humans and animals, increase in demand for DNA vaccines owing to its advantages such as low risk of infection, easy transportation and stability at room temperature. In addition, increase in number of antibiotics resistant pathogens has created the need for effective and low-cost vaccination such as DNA vaccines, which would provide long lasting immunity, further boost growth of the DNA vaccines market.

However, lack of immunogenicity associated with DNA vaccines may hamper the growth of the market. Furthermore, limited knowledge of the effects of DNA vaccines on humans is also expected to limit the growth of the market. In contrast, development of novel vaccines using DNA technology, and high growth potential in untapped emerging economies are some factors that are expected to offer lucrative growth opportunities for players in the DNA vaccines market.

The global DNA vaccines market is segmented on the basis of product type, type, end user, and region to provide a detailed assessment of the market. By product type, it is segmented into Oncept, West Nile-Innovator, and Apex-IHN. By type, the market is segmented into therapeutic vaccines and prophylactic vaccines. Based on end user, it is categorized into veterinary clinics, veterinary hospitals. Region wise, the market is analyzed only across North America as DNA vaccine products have not been approved in the other regions.

KEY BENEFITS FOR STAKEHOLDERS

  • The study provides an in-depth analysis of the DNA vaccines market along with the current trends and future estimations to explain the imminent investment pockets.
  • A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
  • Comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
  • Extensive analysis of the key segments of the industry helps to understand the application and products of DNA vaccines used across the globe.
  • Key market players and their strategies have been analyzed to understand the competitive outlook of the market.

KEY MARKET SEGMENTS


By Product Type

  • Oncept
  • West Nile-Innovator
  • Apex-IHN

By Type

  • Therapeutic Vaccines
  • Prophylactic Vaccines

By End User

  • Veterinary Clinics
  • Veterinary Hospitals

By Region

  • North America
  • U.S.
  • Canada

LIST OF KEY PLAYERS PROFILED IN THE REPORT

  • BOEHRINGER INGELHEIM GmbH (Merial)
  • ELI-LILLY (Novartis Animal Health)
  • GeneOne Life Science
  • GEOVAX LABS, INC
  • Inovio Pharmaceuticals (VGX Animal Health)
  • Genexine, Inc.
  • VIATRIS INC. (Rottapharm Biotech)
  • Takara Holdings (Takara Bio)
  • ZOETIS INC. (Fort dodge Animal Health)
  • Zydus Cadila
Frequently Asked Questions about the Global DNA Vaccine Market

What is the estimated value of the Global DNA Vaccine Market?

The Global DNA Vaccine Market was estimated to be valued at $422.77 million in 2020.

What is the growth rate of the Global DNA Vaccine Market?

The growth rate of the Global DNA Vaccine Market is 6.2%, with an estimated value of $774.43 million by 2030.

What is the forecasted size of the Global DNA Vaccine Market?

The Global DNA Vaccine Market is estimated to be worth $774.43 million by 2030.

Who are the key companies in the Global DNA Vaccine Market?

Key companies in the Global DNA Vaccine Market include BOEHRINGER INGELHEIM GmbH, ELI, LILLY (Novartis Animal Health), GeneOne Life Science, GEOVAX LABS INC, Inovio Pharmaceuticals (VGX Animal Health), Genexine Inc., VIATRIS INC. (Rottapharm Biotech) and ZOETIS INC. (Fort dodge Animal Health).

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Porter’s five force analysis
3.4. Top player positioning, 2020
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Rise in prevalence of cancer and infectious diseases in humans and animals
3.5.1.2. Increase in demand for DNA vaccines
3.5.1.3. Growth in number of antibiotic resistant pathogens
3.5.2. Restraints
3.5.2.1. Lack of immunogenicity associated with DNA vaccines
3.5.2.2. Limited knowledge about the effects of DNA vaccines on humans
3.5.3. Opportunities
3.5.3.1. Development of novel vaccines using DNA technology
3.5.3.2. High growth potential in untapped emerging economies
3.5.4. Impact analysis
3.6. COVID-19 Impact analysis on the DNA vaccine market
3.7. Human DNA vaccine
CHAPTER 4: DNA VACCINE MARKET, BY PRODUCT TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Oncept
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by country
4.2.3. Market analysis, by country
4.3. West Nile-Innovator
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by country
4.3.3. Market analysis, by country
4.4. Apex-IHN
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by country
4.4.3. Market analysis, by country
CHAPTER 5: DNA VACCINE MARKET, BY TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Therapeutic Vaccines
5.2.1. Market size and forecast, by country
5.2.2. Market analysis, by country
5.3. Prophylactic Vaccines
5.3.1. Market size and forecast, by country
5.3.2. Market analysis, by country
CHAPTER 6: DNA VACCINE MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Veterinary Clinics
6.2.1. Market size and forecast, by country
6.2.2. Market analysis, by country
6.3. Veterinary Hospitals
6.3.1. Market size and forecast, by country
6.3.2. Market analysis, by country
CHAPTER 7: DNA VACCINE MARKET, BY REGION
7.1. Overview
7.2. North America
7.2.1. Key market trends, growth factors, and opportunities
7.2.2. Market size and forecast, by country
7.2.2.1. U.S.
7.2.2.1.1. U.S. DNA vaccine market, by product type
7.2.2.1.2. U.S. DNA vaccine market, by type
7.2.2.1.3. U.S. DNA vaccine market, by end user
7.2.2.2. Canada
7.2.2.2.1. Canada DNA vaccine market, by product type
7.2.2.2.2. Canada DNA vaccine market, by type
7.2.2.2.3. Canada DNA vaccine market, by end user
7.2.3. North America market size and forecast, by product type
7.2.4. North America market size and forecast, by type
7.2.5. North America market size and forecast, by end user
CHAPTER 8: COMPANY PROFILES
8.1. BOEHRINGER INGELHEIM GmbH (MERIAL)
8.1.1. Company overview
8.1.2. Operating business segments
8.1.3. Product portfolio
8.1.4. Business performance
8.2. ELI-LILLY (NOVARTIS ANIMAL HEALTH)
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.3. GENEONE LIFE SCIENCE
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.4. GEOVAX LABS, INC.
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.5. INOVIO PHARMACEUTICALS (VGX ANIMAL HEALTH)
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.6. GENEXINE, INC.
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.7. VIATRIS INC. (ROTTAPHARM BIOTECH)
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product Portfolio
8.7.5. Business performance
8.8. TAKARA HOLDINGS (TAKARA BIO)
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.9. ZOETIS INC. (FORT DODGE ANIMAL HEALTH)
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.10. ZYDUS CADILA
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
8.10.6. Key strategic moves and developments
List of Tables
TABLE 01. GLOBAL DNA VACCINES MARKET, BY PRODUCT TYPE, 2020-2030($MILLION)
TABLE 02. DNA VACCINE MARKET FOR ONCEPT, BY COUNTRY, 2020-2030($MILLION)
TABLE 03. DNA VACCINE MARKET FOR WEST NILE-INNOVATOR, BY COUNTRY, 2020-2030($MILLION)
TABLE 04. DNA VACCINE MARKET FOR APEX-IHN, BY COUNTRY, 2020-2030($MILLION)
TABLE 05. GLOBAL DNA VACCINE MARKET, BY TYPE, 2020-2030($MILLION)
TABLE 06. DNA VACCINE MARKET FOR THERAPEUTIC VACCINE, BY COUNTRY, 2020-2030($MILLION)
TABLE 07. DNA VACCINE MARKET FOR PROPHYLACTIC VACCINES, BY COUNTRY, 2020-2030($MILLION)
TABLE 08. GLOBAL DNA VACCINE MARKET, BY END USER, 2020-2030($MILLION)
TABLE 09. DNA VACCINE MARKET FOR VETERINARY CLINICS, BY COUNTRY, 2020-2030($MILLION)
TABLE 10. DNA VACCINE MARKET FOR VETERINARY HOSPITALS, BY COUNTRY, 2020-2030($MILLION)
TABLE 11. NORTH AMERICA DNA VACCINE MARKET, BY COUNTRY, 2020-2030($MILLION)
TABLE 12. U.S. DNA VACCINE MARKET, BY PRODUCT TYPE, 2020-2030($MILLION)
TABLE 13. U.S. DNA VACCINE MARKET, BY TYPE, 2020-2030($MILLION)
TABLE 14. U.S. DNA VACCINE MARKET, BY END USER, 2020-2030($MILLION)
TABLE 15. CANADA DNA VACCINE MARKET, BY PRODUCT TYPE, 2020-2030($MILLION)
TABLE 16. CANADA DNA VACCINE MARKET, BY TYPE, 2020-2030($MILLION)
TABLE 17. CANADA DNA VACCINE MARKET, BY END USER, 2020-2030($MILLION)
TABLE 18. NORTH AMERICA DNA VACCINE MARKET, BY PRODUCT TYPE, 2020-2030($MILLION)
TABLE 19. NORTH AMERICA DNA VACCINE MARKET, BY TYPE, 2020-2030($MILLION)
TABLE 20. NORTH AMERICA DNA VACCINE MARKET, BY END USER, 2020-2030($MILLION)
TABLE 21. BOEHRINGER: COMPANY SNAPSHOT
TABLE 22. BOEHRINGER: OPERATING SEGMENTS
TABLE 23. BOEHRINGER: PRODUCT PORTFOLIO
TABLE 24. LILLY:COMPANY SNAPSHOT
TABLE 25. LILLY: OPERATING SEGMENTS
TABLE 26. LILLY: PRODUCT PORTFOLIO
TABLE 27. GENEONE : COMPANY SNAPSHOT
TABLE 28. LILLY: OPERATING SEGMENTS
TABLE 29. GENEONE: PRODUCT PORTFOLIO
TABLE 30. GEOVAX: COMPANY SNAPSHOT
TABLE 31. GEOVAX: OPERATING SEGMENTS
TABLE 32. GEOVAX: PRODUCT PORTFOLIO
TABLE 33. INOVIO: COMPANY SNAPSHOT
TABLE 34. INOVIO: OPERATING SEGMENTS
TABLE 35. INOVIO: PRODUCT PORTFOLIO
TABLE 36. GENEXINE, INC.: COMPANY SNAPSHOT
TABLE 37. GENEXINE, INC: OPERATING SEGMENTS
TABLE 38. GENEXINE, INC: PRODUCT PORTFOLIO
TABLE 39. VIATRIS: COMPANY SNAPSHOT
TABLE 40. VIATRIS : OPERATING SEGMENTS
TABLE 41. VIATRIS: PRODUCT PORTFOLIO
TABLE 42. TAKARA HOLDINGS: COMPANY SNAPSHOT
TABLE 43. TAKARA BIO: OPERATING SEGMENTS
TABLE 44. TAKARA HOLDINGS: PRODUCT PORTFOLIO
TABLE 45. ZOETIS: COMPANY SNAPSHOT
TABLE 46. ZOETIS: OPERATING SEGMENTS
TABLE 47. ZOETIS: PRODUCT PORTFOLIO
TABLE 48. CADILA: COMPANY SNAPSHOT
TABLE 49. CADILA: OPERATING SEGMENTS
TABLE 50. CADILA: PRODUCT PORTFOLIO
List of Figures
FIGURE 01. DNA VACCINE MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. LOW BARGAINING POWER OF SUPPLIERS
FIGURE 04. MODERATE BARGAINING POWER OF BUYERS
FIGURE 05. MODERATE THREAT OF SUBSTITUTES
FIGURE 06. MODERATE THREAT OF NEW ENTRANTS
FIGURE 07. HIGH INTENSITY OF RIVALRY
FIGURE 08. TOP PLAYER POSITIONING, 2020
FIGURE 09. IMPACT ANALYSIS
FIGURE 10. HUMAN DNA VACCINE MARKET
FIGURE 11. COMPARATIVE ANALYSIS OF DNA VACCINE MARKET FOR ONCEPT, BY COUNTRY, 2020 & 2030 (%)
FIGURE 12. COMPARATIVE ANALYSIS OF DNA VACCINE MARKET FOR WEST NILE-INNOVATOR, BY COUNTRY, 2020 & 2030 (%)
FIGURE 13. COMPARATIVE ANALYSIS OF DNA VACCINE MARKET FOR APEX-IHN, BY COUNTRY, 2020 & 2030 (%)
FIGURE 14. COMPARATIVE ANALYSIS DNA VACCINE MARKET FOR THERAPEUTIC VACCINES, BY COUNTRY, 2020 & 2030 (%)
FIGURE 15. COMPARATIVE ANALYSIS OF DNA VACCINE MARKET FOR PROPHYLACTIC VACCINES, BY COUNTRY, 2020 & 2030 (%)
FIGURE 16. COMPARATIVE ANALYSIS OF DNA VACCINE MARKET FOR VETERINARY CLINICS, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 17. COMPARATIVE ANALYSIS OF DNA VACCINE MARKET FOR VETERINARY HOSPITALS, BY COUNTRY, 2020 & 2030 (%)
FIGURE 18. BOEHRINGER: REVENUE, 2018-2020 ($MILLION)
FIGURE 19. BOEHRINGER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 20. BOEHRINGER: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 21. LILLY: NET SALES 2018-2020 ($MILLION)
FIGURE 22. LILLY: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 23. GEOVAX: NET SALES 2018-2020 ($MILLION)
FIGURE 24. INOVIO: NET SALES, 2018-2020, ($MILLION)
FIGURE 25. VIATRIS: NET SALES, 2018-2020 ($MILLION)
FIGURE 26. VIATRIS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 27. VIATRIS: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 28. TAKARA HOLDINGS: NET SALES, 2019-2021, ($MILLION)
FIGURE 29. TAKARA HOLDINGS: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 30. ZOETIS: NET SALES, 2018-2020 ($MILLION)
FIGURE 31. ZOETIS: REVENUE SHARE BY PRODUCT, 2020 (%)
FIGURE 32. ZOETIS: REVENUE SHARE BY REGION, 2020(%)
FIGURE 33. CADILA: NET SALES, 2019-2021 ($MILLION)
FIGURE 34. CADILA: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 35. CADILA: REVENUE SHARE BY REGION, 2021 (%)

Companies Mentioned

  • BOEHRINGER INGELHEIM GmbH
  • ELI-LILLY (Novartis Animal Health)
  • GeneOne Life Science
  • GEOVAX LABS INC
  • Inovio Pharmaceuticals (VGX Animal Health)
  • Genexine Inc.
  • VIATRIS INC. (Rottapharm Biotech)
  • Takara Holdings (Takara Bio)
  • ZOETIS INC. (Fort dodge Animal Health)
  • Zydus Cadila

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...